|
May 27
|
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
|
|
May 22
|
Galmed Pharmaceuticals: Q1 Earnings Snapshot
|
|
May 22
|
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 6
|
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
|
|
Apr 28
|
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
|
|
Sep 25
|
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
|
|
Apr 4
|
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
|
|
Mar 15
|
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
|